Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Tremelimumab in Recurrent/Metastatic Head and Neck Cancer
NCT02262741Phase 1Completed
- Sponsor
- MedImmune
- Start
- Oct 2014
- Primary completion
- Sep 2017
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of durvalumab and tremelimumab in head and neck squamous cell carcinoma (HNSCC), sponsored by MedImmune. Primary endpoints: Number of subjects reporting adverse events, Number of subjects reporting serious adverse events and 1 more. Started Oct 2014; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02262741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262741.